HDM 1005
Alternative Names: HDM-1005Latest Information Update: 28 Oct 2025
At a glance
- Originator Hangzhou Zhongmei Huadong Pharmaceutical
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 20 Jun 2025 Adverse events, pharmacokinetics and pharmacodynamics data from a phase Ia and phase Ib trial in Obesity presented at the 85th Annual Scientific Sessions of the American Diabetes Association (ADA-2025)
- 30 Apr 2025 Phase-II clinical trials in Type 2 diabetes mellitus in China (SC) (NCT07109700)
- 14 Feb 2025 Hangzhou Zhongmei Huadong Pharmaceutical completes a phase Ib trial in Obesity (In volunteers) in China (SC) (NCT06637020) (CTR20241919)